Be part of the knowledge.™

Neurology and Neurosurgery

2541

LikeLikedUnlike

31-45 of 778

Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
NeuroFrontiers
Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- David Kimhy, PhD
  Peer
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
- Alexandria May, PharmD, BCPS
  Peer
- Angela Waanders, MD, MPH, MS
  Peer
- Ashley S. Margol, MD, MS
  Peer
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
Clinician's Roundtable
Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Caterina Garone, MD, PhD
  Peer
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
Clinician's Roundtable
Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Cristina Domínguez González, MD, PhD
  Peer
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
Clinician's Roundtable
Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Philip Yeske, PhD
  Peer
Advancing gMG Care: Conversations with Clinicians at AANEM
NeuroFrontiers
Advancing gMG Care: Conversations with Clinicians at AANEM
- Marlene Mimi Maeusli, PhD.
  Peer
- Michael Weiss, MD
  Peer
- Joshua Alpers, MD
  Peer
- James F. Howard, Jr, MD
  Peer
- Omar Sinno, MD
  Peer
- Rodrigo Rodriguez, MD
  Peer
- Sheetal Shroff, MD
  Peer
advertisement
Personalizing Treatment for gMG: On the Ground at AANEM
NeuroFrontiers
Personalizing Treatment for gMG: On the Ground at AANEM
- Marlene Mimi Maeusli, PhD.
  Peer
- Rodrigo Rodriguez, MD
  Peer
- Sheetal Shroff, MD
  Peer
- Joshua Alpers, MD
  Peer
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiers
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiers
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiers
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
- Ryan Quigley
  Peer
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiers
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
- Sheetal Shroff, MD
  Peer
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
- Michael Weiss, MD
  Peer
advertisement
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
- Omar Sinno, MD
  Peer
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's Roundtable
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
- Stephen Wong, PhD
  Peer
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiers
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis

Program Chapters

Segment Chapters

Playlist:

Recommended